Improved Progression-Free, Overall Survival Achieved With Dabrafenib, Trametinib Combo in Melanoma

Dabrafenib plus trametinib achieves good overall and progression-free survival in BRAF inhibitor-naïve patients with melanoma.
Dabrafenib plus trametinib achieves good overall and progression-free survival in BRAF inhibitor-naïve patients with melanoma.

Dabrafenib plus trametinib achieves good overall and progression-free survival in BRAF inhibitor-naïve patients with BRAF V600 mutation-positive metastatic melanoma, a study published online ahead of print in the Journal of Clinical Oncology has shown.1

This analysis reports on the overall survival (OS) and clinical characteristics of BRAF inhibitor–naive long-term responders and survivors treated with dabrafenib plus trametinib from a phase I and II study of patients with BRAF V600 mutation-positive metastatic melanoma.

This analysis included 78 BRAF inhibitor–naive patients treated with dabrafenib 150 mg twice daily plus trametinib 2 mg daily (the 150/2 group): 24 patients were from the nonrandomly assigned (part B) cohort and 54 patients were from the randomly assigned (part C) cohort of the trial.

Progression-free and OS were analyzed separately; baseline characteristics and factors on treatment were analyzed for associations with durable responses and OS.

Progression-free survival was 44%, 22%, and 18% at 1, 2, and 3 years, respectively, for the part B group; and 41%, 25%, and 21% at 1, 2, and 3 years, respectively, for the part C group.

Median OS was 27.4 months for the part B group and 25 months for the part C group. OS for the part B group was 72%, 60%, and 47% at 1, 2, and 3 years, respectively; OS for the part C group was 80%, 51%, and 38%, respectively, at 1, 2, and 3 years, respectively.

Metastases in fewer than 3 organ sites and lower baseline lactate dehydrogenase were associated with prolonged survival. At 3 years, OS was 62% in patients with normal baseline lactate dehydrogenase and 63% in patients with a complete response.

The study results show a median OS of more than 2 years in BRAF inhibitor-naïve patients with BRAF V600 mutation-positive metastatic melanoma who received dabrafenib plus trametinib. In addition, approximately 20% of patients receiving this regimen were progression free at 3 years.

REFERENCE

1. Long GV, Weber JS, Infante JR, et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib [published online ahead of print January 25, 2016]. J Clin Oncol. doi:10.1200/JCO.2015.62.9345.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs